A Randomized, Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared with a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet under Fasting Conditions in Healthy Male Subjects

Inclusion Criteria:

• Age between 20 and 40
• Signed informed consent

Exclusion Criteria:

• Has a history of hypersensitivity to IP ingredients
• Hypertension or hyportension